Dosing & Uses
Dosage Forms & Strengths
injection, lyophilized powder for reconstitution
- 100mg/single-use vial
Factor Xa Reversal
Indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed because of life-threatening or uncontrolled bleeding
There are 2 dosage regimens (low dose or high dose) to choose from
Safety and efficacy of an additional dose has not been established
Low or high dose regimens
-
Low dose
- Initial IV bolus: 400 mg IV; target infusion rate of 30 mg/min
- Follow-on IV infusion: 4 mg/min IV for up to 120 min
-
High dose
- Initial IV bolus: 800 mg IV; target infusion rate of 30 mg/min
- Follow-on IV infusion: 8 mg/min IV for up to 120 min
Dose based on rivaroxaban or apixaban dose
-
Use low dose described above
- Rivaroxaban dose ≤10 mg (any timing from last dose)
- Apixaban dose ≤5 mg (any timing from last dose)
- Rivaroxaban >10 mg or dose unknown (≥8 hr from last dose)
- Apixaban >5 mg or dose unknown (≥8 hr from last dose)
-
Use high dose described above
- Rivaroxaban >10 mg or dose unknown (<8 hr from last dose or unknown)
- Apixaban >5 mg or dose unknown (<8 hr from last dose or unknown)
Dosing Considerations
Accelerated approval
- Approved under accelerated approval based on the change from baseline in anti-FXa activity in healthy volunteers
- An improvement in hemostasis has not been established
- Continued approval for this indication may be contingent upon the results of studies to demonstrate an improvement in hemostasis in patients
Limitation of use
- Has not been shown effective for, and is not indicated for, treatment of bleeding related to any FXa inhibitors other than apixaban and rivaroxaban
Restarting antithrombotic therapy
- Patients treated with FXa inhibitor therapy have underlying disease states that predispose them to thromboembolic events, thus reversing FXa inhibitor therapy exposes patients to the thrombotic risk of their underlying disease
- To reduce the risk of thrombosis, resume anticoagulant therapy as soon as medically appropriate after dose
Safety and efficacy not established
Adverse Effects
>10%
Infusion-related reactions (18%)
Thromboembolic events
- Note: 33% of patients were on antithrombotic therapy at time of event
- Deep vein thrombosis (33%)
- Ischemic stroke (24%)
- Acute myocardial infarction (15%)
- Pulmonary embolism (15%)
Deaths due to bleeding <30 days postdose
- 25 deaths (14%)
By bleeding type, patient deaths
- Intracranial bleeding (14%)
- GI bleeding (10%)
- Other bleeding types (19%)
1-10%
Thromboembolic events
- Note: 33% of patients were on antithrombotic therapy at time of event
- Cardiogenic shock (9%)
- Sudden death (6%)
- CHF (6%)
- Acute respiratory failure (6%)
- Cardiac arrest (3%)
- Cardiac thrombus (3%)
- Embolic stroke (3%)
- Iliac artery thrombosis (3%)
- Nonsustained ventricular tachycardia (3%)
Warnings
Black Box Warnings
Serious and life-threatening adverse effects
- Monitor for thromboembolic events and initiate anticoagulation when medically appropriate
- Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed
Treatment has been associated with the following serious and life-threatening adverse events, including
- Arterial and venous thromboembolic events
- Ischemic events, including myocardial infarction and ischemic stroke
- Cardiac arrest
- Sudden deaths
Contraindications
None
Cautions
Thromboembolic and ischemic risks
- Monitor patients for signs and symptoms of arterial and venous thromboembolic events, ischemic events, and cardiac arrest
- To reduce thromboembolic risk, resume anticoagulant therapy as soon as medically appropriate following therapy
- Safety not evaluated in patients who experienced thromboembolic events or disseminated intravascular coagulation within two weeks prior to life-threatening bleeding event requiring treatment with this drug
- Safety also not evaluated in patients who received prothrombin complex concentrates, recombinant factor VIIa, or whole blood products within seven days prior to the bleeding event
Reelevation or incomplete reversal of anti-FXa activity
- Compared wtih baseline, the ANNEXA-4 clinical trial observed a rapid and substantial decrease in anti-FXa activity corresponding to the IV bolus that was sustained through the end of the continuous infusion
- Following the infusion, there was an increase in anti-FXa activity, which peaked 4 hr after infusion
- After this peak, the antiFXa activity decreased at a rate similar to the clearance of the FXa inhibitors
- ~50% of patients experience >90% decrease from baseline anti-FXa activity after administration
Pregnancy
Pregnancy
Data are not available in pregnant women to inform patients of associated risks
Safety during labor and delivery has not been evaluated
Animal reproductive and development studies have not been conducted
Lactation
Data are not available regarding the presence in human milk, the effects on the breastfed child, or the effects on milk production
The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Exerts its procoagulant effect by binding and sequestering the FXa inhibitors, rivaroxaban and apixaban
Another observed procoagulant effect is its ability to bind and inhibit the activity of tissue factor pathway inhibitor (TFPI); inhibiting TFPI activity can increase tissue factor-initiated thrombin generation
Distribution
Vd: 5 L; ~equivalent to blood volume
Elimination
Half-life: 5-7 hr
Clearance: 4.3 L/hr
Administration
IV Preparation
Reconstitution
- Reconstitute each 100-mg vial using a 10-mL syringe and ≥20-gauge needle
- Slowly inject 10 mL sterile water for injection; direct solution onto the inside wall of the vial to minimize foaming
- Resulting concentration is 10 mg/mL
- To reduce the total reconstitution time needed during preparation, reconstitute all required vials in succession
- Low dose requires 4 vials for bolus and 5 vials for infusion
- High dose requires 8 vials for bolus and 10 vials for infusion
- Ensure dissolution by gently swirling each vial; do not shake (may lead to foaming); typical dissolution time is 3 minutes; discard vial if dissolution is incomplete
- Upon reconstitution, visually inspect solution for particulate matter and discoloration prior to administration; solution should appear clear, colorless to slightly yellow
IV bolus preparation
- Use ≥60-mL syringe with ≥20-gauge needle to withdraw the reconstituted solution from each vial until the required dosing volume is achieved
- Note the total volume withdrawn into the syringe
- Transfer solution from the syringe into an empty polyolefin or PVC IV bag with a volume of ≤250 mL
- Discard syringe, needle, and vials, including any unused portion of drug
Continuous IV infusion preparation
- Follow the same procedure outlined above for reconstitution and IV bolus preparation
- More than one 40- to 60-mL syringe, or an equivalent 100-mL syringe, may be used for transfer of reconstituted solution to the IV bag
IV Administration
Administer intravenously, using a 0.2- or 0.22-micron in-line polyether sulfone or equivalent low protein-binding filter
Start the bolus at a target rate of ~30 mg/minute
Within 2 minutes following the bolus dose, administer the continuous IV infusion for up to 120 minutes
Storage
Does not contain preservatives
Unopened vials
- Refrigerate at 2-8°C (36-46°F)
- Do not freeze
Reconstituted solution
In vials
- Room temperature for up to 8 hr, or
- Refrigerate at 2-8°C for up to 24 hr
In IV bags
- Room temperature for up to 8 hr, or
- Refrigerate at 2-8°C for up to 16 hr
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.